Skip to main content
    I

    Insmed Inc (INSM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $99.21
    +1.42 (+1.45%)

    Market Cap: $21.36B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    33%(13/39)
    Avg Surprise
    -9.57%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.37
    Range$-0.90 - $-0.09
    17 analysts
    EPS Revisions
    3
    0
    7d
    12
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.61+38.9%
    60d ago$-0.33-14.5%
    30d ago$-0.36-3.5%
    7d ago$-0.36-2.5%
    Current$-0.37
    Revenue Consensus
    $499M
    Range$457M - $524M
    20 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.48
    Range$-0.59 - $1.32
    18 analysts
    Revenue Consensus
    $609M
    Range$468M - $693M
    22 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.48---
    Sep 26EST
    		-$-0.37---
    Jun 26
    Reported Aug 6
    		$-0.52$-0.69+24.64%Beat+69.4%
    Mar 26
    Reported May 7
    		$-0.76$-1.00+24.00%Beat+46.5%
    Dec 25
    Reported Feb 19
    		$-1.54$-1.17-31.62%Miss-16.7%
    Sep 25
    Reported Oct 30
    		$-1.75$-1.37-27.74%Miss-37.8%
    Jun 25
    Reported Aug 7
    		$-1.70$-1.30-30.77%Miss+12.4%
    Mar 25
    Reported May 8
    		$-1.42$-1.20-18.33%Miss-34.0%
    Dec 24
    Reported Feb 20
    		$-1.32$-1.23-7.32%Miss-3.1%
    Sep 24
    Reported Oct 31
    		$-1.27$-1.22-4.10%Miss-14.4%
    Jun 24
    Reported Aug 8
    		$-1.94$-1.23-57.72%Miss-9.0%
    Mar 24
    Reported May 9
    		$-1.06$-1.20+11.67%Beat+9.4%
    Dec 23
    Reported Feb 22
    		$-1.28$-1.13-13.27%Miss-5.8%
    Sep 23
    Reported Oct 26
    		$-1.11$-1.11+0.00%Beat-1.8%
    Jun 23
    Reported Aug 3
    		$-1.78$-1.12-58.93%Miss-122.5%
    Mar 23
    Reported May 4
    		$-1.17$-1.10-6.36%Miss-46.2%
    Dec 22
    Reported Feb 23
    		$-1.21$-1.04-16.35%Miss-27.4%
    Sep 22
    Reported Oct 27
    		$-1.09$-0.87-25.29%Miss-13.5%
    Jun 22
    Reported Aug 4
    		$-0.80$-0.89+10.11%Beat+12.1%
    Mar 22
    Reported May 5
    		$-0.80$-0.87+8.05%Beat+10.1%
    Dec 21
    Reported Feb 17
    		$-0.95$-0.86-10.47%Miss+5.0%
    Sep 21
    Reported Oct 28
    		$-0.96$-0.78-23.08%Miss-52.4%
    Jun 21
    Reported Aug 5
    		$-0.91$-0.88-3.41%Miss-42.2%
    Mar 21
    Reported May 6
    		$-0.89$-0.96+7.29%Beat-20.3%
    Dec 20
    Reported Feb 25
    		$-1.00$-0.70-42.86%Miss-69.5%
    Sep 20
    Reported Oct 29
    		$-0.63$-0.59-6.78%Miss+7.4%
    Jun 20
    Reported Aug 6
    		$-0.64$-0.62-3.23%Miss+21.0%
    Mar 20
    Reported Apr 30
    		$-0.74$-0.72-2.78%Miss+22.9%
    Dec 19
    Reported Feb 25
    		$-0.59$-0.58-1.72%Miss+50.4%
    Sep 19
    Reported Oct 30
    		$-0.68$-0.67-1.49%Miss+40.4%
    Jun 19
    Reported Aug 1
    		$-0.81$-0.86+5.81%Beat+19.0%
    Mar 19
    Reported May 7
    		$-0.96$-1.00+4.00%Beat-10.3%
    Dec 18
    Reported Feb 22
    		$-1.19$-1.05-13.33%Miss-40.0%
    Sep 18
    Reported Oct 30
    		$-1.14$-1.06-7.55%Miss-65.2%
    Jun 18
    Reported Aug 2
    		$-1.00$-1.06+5.66%Beat-38.9%
    Mar 18
    Reported May 2
    		$-0.87$-0.96+9.38%Beat-45.0%
    Dec 17
    Reported Feb 23
    		$-0.85$-0.64-32.81%Miss+22.7%
    Sep 17
    Reported Nov 2
    		$-0.69$-0.70+1.43%Beat-
    Jun 17
    Reported Aug 3
    		$-0.72$-0.63-14.29%Miss-
    Mar 17
    Reported May 3
    		$-0.60$-0.60+0.00%Beat-
    Dec 16
    Reported Feb 23
    		$-1.10$-0.89-23.60%Miss-

    Key Metrics

    Valuation
    P/E Ratio-21.71EV/EBITDAN/A
    Price/FCF-26.70xFCF Yield-3.75%
    Profitability
    Profit Margin-76.90%Operating Margin-23.80%
    ROE-87.20%ROIC-64.90%
    Financial Health
    Debt/Equity0.72xInterest CoverageN/A
    Current Ratio3.72xQuick Ratio3.40x
    Trading Statistics
    Beta0.82Avg Volume2.75M
    52-Week High$212.7552-Week Low$90.39

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$101.53
    SMA 20$109.55
    SMA 50$119.60
    SMA 200$129.48
    EMA 10$102.13
    EMA 20$107.48
    EMA 50$113.36
    EMA 200$123.42

    MACD

    Line: -6.22Signal: -5.05Hist: -1.16

    ADX

    ADX: 40.7+DI: 11.4-DI: 32.5

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down96.0
    PSAR$105.51

    Bollinger Bands

    Upper Band$127.83
    Lower Band$91.26
    %B Position3338%(Upper)
    Band Width0.22

    RSI (14-Day)

    Neutral
    31.9

    Momentum Oscillators

    Stoch %K7.7
    Stoch %D6.9
    Williams %R-85.4
    ROC (10d)-8.6%
    Momentum-9.38
    CCI (20d)-84.2
    MFI (14d)21.5

    Volatility Measures

    ATR (14d)$4.46(4.5%)
    StdDev (20d)9.14
    Hist Vol38.3%(Moderate)

    Volume Flow

    VWAP$99.28
    OBV50.4M
    AD Line60.3M
    CMF (20d)-0.125

    Volume Metrics

    Avg Vol (20d)2.9M
    Vol Ratio1.2x
    VWMA (20d)$108.45

    Pivot Points

    R3$100.85
    R2$99.42
    R1$98.61
    Pivot Point$97.18
    S1$96.37
    S2$94.94
    S3$94.13

    Advanced Oscillators

    TSI-35.58
    Ultimate Osc41.4
    KST-165.14

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$425.49M$305.96M$263.84M$142.34M$107.42M$92.82M$104.44M$93.42M$90.34M$75.50M$83.69M$79.07M
    Cost of Revenue$67.21M$47.42M$44.22M$29.36M$28.07M$21.28M$26.15M$21.17M$20.96M$17.46M$18.44M$16.71M
    Gross Profit$358.27M$258.54M$219.62M$112.98M$79.34M$71.55M$78.29M$72.25M$69.38M$58.04M$65.25M$62.37M
    Operating Expenses$359.82M$411.86M$539.37M$478.98M$392.22M$319.69M$308.70M$285.68M$358.28M$203.55M$243.52M$210.03M
    R&D$210.03M$209.49M$254.91M$186.41M$177.19M$152.58M$179.73M$150.81M$146.75M$121.08M$137.03M$109.15M
    SG&A$247.47M$247.26M$212.48M$186.38M$154.76M$147.54M$142.51M$118.93M$106.57M$93.10M$89.53M$90.63M
    Operating Income$-1,548,000$-153,320,000$-319,748,000$-366,005,000$-312,876,000$-248,140,000$-230,414,000$-213,429,000$-288,904,000$-145,505,000$-178,272,000$-147,668,000
    Interest Income$10.98M$12.04M$0$0$13.22M$13.91M$17.26M$16.98M$10.29M$8.78M$9.85M$10.58M
    Interest Expense$20.27M$20.08M$7.19M$2.70M$21.25M$21.57M$21.55M$21.05M$21.27M$21.04M$20.78M$20.29M
    Income Before Tax$-11,373,000$-162,098,000$-326,934,000$-368,701,000$-320,443,000$-255,671,000$-234,282,000$-219,510,000$-299,771,000$-156,502,000$-185,063,000$-158,389,000
    Income Tax Expense$1.87M$1.47M$1.55M$1.32M$1.24M$912,000$1.27M$1.01M$838,000$589,000$998,000$544,000
    Net Income$-13,242,000$-163,563,000$-328,485,000$-370,021,000$-321,686,000$-256,583,000$-235,548,000$-220,524,000$-300,609,000$-157,091,000$-186,061,000$-158,933,000
    EBITDA$5.29M$-146,981,000$-313,956,000$-360,592,000$-306,322,000$-242,362,000$-224,822,000$-210,553,000$-283,612,000$-138,863,000$-170,614,000$-142,109,000
    EBIT$-2,079,000$-154,056,000$-321,571,000$-366,608,000$-312,423,000$-248,008,000$-229,989,000$-215,438,000$-288,789,000$-144,243,000$-175,782,000$-147,383,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about INSM

    Government Contracts

    Gov Obligations (TTM)
    -$29404
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    2
    New Awards (TTM)
    1
    Avg Remaining Term
    N/A

    Recent Awards

    Award IDAgencyObligatedStart
    36C24526N0641Department of Veterans AffairsDepartment of Veterans Affairs$31229Jun 10, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    INSM: 2025 Launch Will Drive Respiratory Platform Expansion Amid Elevated Expectations

    Insmed (INSM) is poised for significant growth driven by the anticipated 2025 launch of brensocatib for non-cystic fibrosis bronchiectasis and potential label expansion for ARIKAYCE. Analysts maintain a generally...

    Simply Wall Street•10/15/26•Somewhat-Bullish

    Insmed (INSM) Could Be 50% Undervalued After TPIP Phase 3 Push

    Insmed (INSM) is gaining attention after highlighting its TPIP clinical development program, contributing to a mixed recent stock performance. Despite a 43.99% year-to-date drop...

    Simply Wall Street•10/15/26•Somewhat-Bullish

    UBS maintains USD 172.00 target for Insmed stock

    UBS has reaffirmed its Buy rating and a USD 172.00 price target for Insmed (INSM) stock, indicating a significant upside from its current Nasdaq price. This comes as Insmed prepares to release its third-quarter results...

    ad-hoc-news.de•10/15/26•Bullish

    When Can We Expect A Profit From Insmed Incorporated (NASDAQ:INSM)?

    This article analyzes Insmed Incorporated's path to profitability, focusing on analyst estimates for when the company is expected to break even. It highlights that the average analyst forecast predicts Insmed will become...

    Moomoo•10/15/26•Somewhat-Bullish

    Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026

    Insmed Incorporated announced it will feature its global PALM Clinical Development Program at CHEST 2026. This program involves four parallel Phase 3 studies evaluating treprostinil palmitil inhalation powder (TPIP)...

    Insmed Incorporated Investor Relations•10/15/26•Bullish

    INSM Valuation and Fair Value

    P/E
    -21.7x
    Forward P/E
    97.1x
    P/FCF
    -26.7x
    PEG
    1.1x
    P/B
    28.5x
    See GNG's fair value

    INSM Profitability: Margins, ROIC and FCF

    Gross margin
    83.5%
    Operating margin
    -23.8%
    Net margin
    -76.9%
    ROIC
    -64.9%
    ROE
    -87.2%
    FCF margin
    -71.0%
    FCF yield
    -3.7%

    INSM Competitors

    CompanyTicker
    Tenet Healthcare CorporationTHC
    STERIS plcSTE
    Incyte CorporationINCY
    Viatris IncVTRS
    Genmab ASGMAB
    EXACT Sciences CorporationEXAS
    United Therapeutics CorporationUTHR
    Zimmer Biomet Holdings IncZBH

    Sector: Healthcare

    INSM Analyst Ratings

    Consensus
    Buy
    Analysts
    24
    Strong Buy
    5
    Buy
    19
    Hold
    0
    Sell
    0
    Strong Sell
    0

    INSM Bull Case vs Bear Case

    Bull case

    • INSM grew quarterly revenue 296.1% year over year.
    • 100.0% of INSM's analyst ratings are Buy or Strong Buy.

    Bear case

    • INSM has a -76.9% net profit margin.
    • INSM beat EPS estimates in 25.0% of its last 8 reported quarters.

    INSM Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -8.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.37
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    12 up, 1 down

    Frequently Asked Questions About INSM

    Does INSM pay dividends?

    Insmed Inc (INSM) does not currently pay a regular dividend.

    What is INSM's market cap?

    Insmed Inc (INSM) has a market capitalization of $21.36B with a current stock price of $99.21.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In